Overview

Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

Status:
Completed
Trial end date:
2017-11-02
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Bayer
Kim's Eye Hospital
Seoul National University Bundang Hospital
Treatments:
Aflibercept
Endothelial Growth Factors
Criteria
Inclusion Criteria:

- polypoidal choroidal vasculopathy without active polyp

- decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

Exclusion Criteria:

- polypoidal choroidal vasculopathy with active polyp

- previous photodynamic therapy more than three times

- anti-VEGF injection within one month

- photodynamic therapy or intraocular steroid treatment within three months